|Rapid Review Complete
|For the management of acute moderate to severe pain in adult patients
|Rapid review commissioned
|Rapid review resubmission required
|Rapid review completed
|Rapid review outcome
|A full HTA is not recommended. The NCPE recommends that sufentanil citrate not be considered for reimbursement at the submitted price*.
*This recommendation should be considered while also having regard to the criteria specified in
the Health (Pricing and Supply of Medical Goods) Act 2013.